RA Vaccination Schedule — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Annual influenza and COVID boosters per schedule plus pneumococcal per immunosuppression schedule plus Shingrix; all inactivated vaccines safe on biologics; live vaccines contraindicated
The best answer is “Annual influenza and COVID boosters per schedule plus pneumococcal per immunosuppression schedule plus Shingrix; all inactivated vaccines safe on biologics; live vaccines contraindicated”. Annual influenza and COVID boosters per schedule plus pneumococcal per immunosuppression schedule plus Shingrix; all inactivated vaccines safe on biologics; live vaccines contraindicated is supported by the cited UK or directly applicable specialist authority and best matches the tested threshold, complication or monitoring principle. The remaining choices—“principally COVID, within a rheumatology pathway, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway, because this is a supported alternative”, “No vaccines on biologics, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist review”, “principally influenza, with clinical reassessment, after specialist assessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment”, “Vaccination unsuitable, within a rheumatology pathway, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment”—are credible in related rheumatology presentations, but each addresses a different diagnosis, investigation, treatment sequence or complication and does not fit the decisive findings in this stem.
Reference: EULAR vaccination recommendations for autoimmune inflammatory rheumatic disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC6943061/